Establishment of a lethal mouse model of emerging tick-borne orthonairovirus infections

PLoS Pathog. 2024 Mar 19;20(3):e1012101. doi: 10.1371/journal.ppat.1012101. eCollection 2024 Mar.

Abstract

Emerging and reemerging tick-borne virus infections caused by orthonairoviruses (family Nairoviridae), which are genetically distinct from Crimean-Congo hemorrhagic fever virus, have been recently reported in East Asia. Here, we have established a mouse infection model using type-I/II interferon receptor-knockout mice (AG129 mice) both for a better understanding of the pathogenesis of these infections and validation of antiviral agents using Yezo virus (YEZV), a novel orthonairovirus causing febrile illnesses associated with tick bites in Japan and China. YEZV-inoculated AG129 mice developed hepatitis with body weight loss and died by 6 days post infection. Blood biochemistry tests showed elevated liver enzyme levels, similar to YEZV-infected human patients. AG129 mice treated with favipiravir survived lethal YEZV infection, demonstrating the anti-YEZV effect of this drug. The present mouse model will help us better understand the pathogenicity of the emerging tick-borne orthonairoviruses and the development of specific antiviral agents for their treatment.

Publication types

  • Validation Study

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Disease Models, Animal
  • Mice
  • Mice, Knockout
  • Nairovirus*
  • Tick-Borne Diseases*

Substances

  • Antiviral Agents

Grants and funding

This work was supported by the Japan Agency for Medical Research and Development (AMED), Japan under grant numbers JP23fk0108644, JP23fk0108625, JP23jf0126002 (K.M.), JP22fk0108637 (Y.O.), JP21wm0125008 (H.S.), by the Ministry of Education, Culture, Sports, Science and Technology (MEXT)/Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan under the grant number JP23H02373, JP23K20041 (K.M.), by the Japan Science and Technology Agency (JST) Moonshot R&D, Japan under the grant number JPMJMS2025 (Y.O.), Ministry of Health, Labour and Welfare (MHLW) under grant 23HA2010 (K.M.), and AMED SCARDA World-leading institutes for vaccine research and development Hokkaido Synergy Campus (223fa627005h0001, H.S. and K.M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.